Fujirebio, AriBio Partnering on Alzheimer's Biomarker Development
Fujirebio will gain access to clinical samples and data collected through AriBio's ongoing Phase III study for its lead anti-Alzheimer's compound AR1001.
Drug Approvals Spark Interest in Alzheimer's Plasma Markers; Utility, Applications Still Uncertain
Blood-based tests offer less invasive and less costly tools for diagnosing and monitoring Alzheimer's, but the field is still establishing which will be most informative.
Fujirebio Europe to Distribute Self-Screen Cervical Cancer Test
The test is designed to detect elevated methylation levels of cervical cancer biomarkers and may be used as a triage follow-up test of HPV-positive women.
Fujirebio Acquires ADx NeuroSciences for €40M
The acquisition will allow Fujirebio to expand its antibody supply business and contract development and manufacturing services in the neurodegenerative field.
Fujirebio Alzheimer's Test Approval Offers Alternative to Imaging, Could Speed Plasma Marker Efforts
The test, which measures β-amyloid in cerebrospinal fluid, received FDA de novo classification, making it the first IVD available for detection of brain amyloid plaques.